AEM vs ICL

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

ICL presents a precarious profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant valuation gap, with the current price ($5.54) trading well above both the Graham Number ($4.33) and the Intrinsic Value ($1.26). While the balance sheet is healthy with low debt (D/E 0.44), the company suffers from razor-thin profit margins (3.16%) and a highly unsustainable dividend payout ratio of 96.39%. Technicals are overwhelmingly bearish (0/100), and the stock has seen a 16.4% decline over the past year, suggesting a lack of market confidence despite a 'hold' analyst consensus.